Document 0519
 DOCN  M9490519
 TI    [Clinical applications of erythropoietin]
 DT    9411
 AU    Robak T; II Kliniki Chorob Wewnetrznych AM w Lodzi.
 SO    Acta Haematol Pol. 1994;25(2 Suppl 1):112-23. Unique Identifier :
       AIDSLINE MED/94346212
 AB    Erythropoietin (EPO) is a glycoprotein produced primarily by the kidney
       in response to tissue hypoxia, and is the principal factor regulating
       red blood cell production. It stimulates erythroid precursors in the
       bone marrow to proliferate and mature into morphologically identifiable
       red blood cells. This hormone acts by binding to specific high-affinity
       receptor on erythroid precursors. Failure to produce adequate quantities
       of EPO leads to severe anemia, a situation most often encountered in
       patients with end stage renal disease. With the application of
       recombinant DNA technology, the gene for this hormone has been
       molecularly cloned, sequenced and expressed in a biologically active
       form in mammalian cells. The recombinant EPO has been demonstrated to
       correct anemia in patients with severe end stage renal disease and
       alleviate their transfusion requirements. It has also been studied for
       anemia associated with HIV infection/zidovudine therapy, in cancer,
       rheumatoid arthritis, and prematurity. In addition it has been studied
       as a facilitator of autologous blood predeposit in patients scheduled
       for elective surgery and as a perisurgical adjuvant to hasten
       hematologic recovery and possibly avoid the need for homologous
       transfusion after elective surgery. When administered with the current
       guidelines EPO appears to be safe drug with favorable risk/benefit
       ratio.
 DE    Acquired Immunodeficiency Syndrome/COMPLICATIONS
       Anemia/ETIOLOGY/*PREVENTION & CONTROL  English Abstract
       Erythropoietin/*THERAPEUTIC USE  Human  Kidney Failure,
       Chronic/COMPLICATIONS  Myelodysplastic Syndromes/THERAPY
       Neoplasms/COMPLICATIONS  Recombinant Proteins  JOURNAL ARTICLE  REVIEW
       REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).